Evercore ISI lowered the firm’s price target on Stryker (SYK) to $405 from $410 and keeps an Outperform rating on the shares. Stryker’s Q3 performance was solid with a 9.5% organic growth, slightly topping Wall Street estimates, mainly driven by Orthopedics’ strong showing, the analyst tells investors in a research note. The firm noted that MedSurg and NeuroTech held steady, though Endoscopy and Medical lagged a bit behind expectations.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker’s Strategic Growth and M&A Focus Earns Buy Rating from Analyst
- Stryker price target raised to $410 from $408 at BTIG
- Stryker’s Strong Revenue Growth and Margin Expansion Drive Buy Rating
- Stryker’s Strong Q3 2025 Performance and Strategic Initiatives Justify Buy Rating
- Stryker Corp Reports Strong Q3 2025 Results